Viking Therapeutics (VKTX) Among Heavily Shorted Biotechs Amid Speculative Investment Surge

Viking Therapeutics (VKTX) has become a focal point for speculative investors due to its elevated short interest, standing at 26.3% of the public float as of March 8, 2026—well above the 10% threshold often seen as a sign of market skepticism. The stock, which trades on the Nasdaq, has seen its short position grow to approximately 9.7 million shares, valued at over $400 million based on the closing price of $41.25 on March 7, 2026. This level of shorting reflects cautious sentiment, despite the company’s pipeline of metabolic disease therapeutics, including VT-302 for non-alcoholic steatohepatitis (NASH) and VT-464 for obesity and type 2 diabetes. The company’s clinical development timeline is central to the current market narrative. Phase 2 trial results for VT-302 are expected by late Q3 2026, with a potential Phase 3 launch anticipated in early 2027. Investors betting against the stock believe these programs face high clinical failure risk and regulatory hurdles, particularly given the competitive landscape with companies like Intercept Pharmaceuticals (ICPT) and Galmed Pharmaceuticals (GLMD). Market dynamics suggest heightened volatility ahead of data milestones. The short squeeze potential remains significant: if positive data triggers a rapid price surge—say, a 50% rally—short sellers could face substantial losses, potentially accelerating momentum. Conversely, negative outcomes could further pressure the stock, which has already declined 38% over the past 12 months. The speculative nature of this trade means that VKTX remains a high-risk, high-reward proposition. Retail traders and hedge funds alike are monitoring the stock closely, with options volume spiking over the past month. While the company maintains a cash runway extending into 2028, any delay in trial timelines could trigger renewed shorting pressure.